New Zealand Observational Ibogaine Study for Addiction Approved by Ethics Committee
On February 22, 2012, MAPS’ new observational study of ibogaine treatment for addiction in New Zealand received final approval (pdf) from the Multi-region Ethics Committee. The new study will take place at the Ibogaine Aotearoa Charitable Trust, an independent ibogaine clinic in New Zealand, and will examine the safety and long-term effectiveness of ibogaine treatment for addiction severity and quality of life in 20 to 30 patients. Since this is an observational study, the study requires no further approvals.
Dr. Geoff Noller, Ph.D., the lead investigator for the study, has now begun recruiting subjects. Dr. Noller is delighted at the recent approval of this internationally-funded study which is a new opportunity to collect quality data on an exciting development in the field of addiction treatment, work of which New Zealand is on the cutting edge. Moreover, comparing data with MAPS’ similar well-advanced study in Mexico will offer further insights into appropriate treatment regimes and international best practices regarding ibogaine. The New Zealand study is based in the South Island city of Dunedin, where the research team will work closely with I.ACT, an experienced Dunedin-based ibogaine treatment provider. Other providers throughout the country have also been approached for participation.